Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0616120230540040169
Korean Journal of Pharmacognosy
2023 Volume.54 No. 4 p.169 ~ p.175
Effect of Isorhamnetin on Inhibition of RANKL-induced Osteoclast Differentiation
Lee Yong-Jin

Jin Ho-Lim
Shin Yoon-A
Lee Eun-Young
Nam Sang-Jip
Son Young-Jin
Abstract
The elderly population is increasing worldwide. Osteoporosis, one of the diseases of the elderly, is a disease that occurs due to a decrease in bone density or changes in bone structure and strength. Osteoporosis mainly occurs in postmenopausal women and the elderly. In the treatment of osteoporosis, it is important to prevent bone loss and inhibit the formation of osteoclasts, which are involved in bone resorption. Research is needed to prevent and treat fractures caused by osteoporosis. In this study, we investigated the effect of isorhamnetin on RANKL-induced osteoclast differentiation. Isorhamnetin significantly inhibited osteoclast differentiation by effectively inhibiting transcription and translation of NFATc1, an essential component in the osteoclast differentiation process. Additionally, the mRNA expression of TRAP, DC-STAMP, and CTSK, genes related to osteoclast differentiation, was suppressed. Therefore, isorhamnetin has the potential to be used as a functional food and therapeutic agent for the treatment of osteoporosis.
KEYWORD
Osteoporosis, Osteoclast, RANKL, NFATc1, Isorhamnetin
FullTexts / Linksout information
Listed journal information